3.295

2.33% 0.075

Pre-market: 3.35 0.055 +1.67%

Elicio Therapeutics Inc (ELTX)

Overview News Price History Discussions Forecast

Elicio Therapeutics Inc stock is traded at $3.295, with a volume of 1.36M. It is up +2.33% in the last 24 hours and down -75.15% over the past month. Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Previous Close:

$3.22

Open:

$3.39

24h Volume:

1.36M

Relative Volume:

1.01

Market Cap:

$62.89M

Revenue:

Net Income/Loss:

$-40.19M

P/E Ratio:

-1.4055

EPS:

-2.3444

Net Cash Flow:

$-38.49M

1W Performance:

-17.62%

1M Performance:

-75.15%

6M Performance:

-59.17%

1Y Performance:

-58.34%

1-Day Range:

$3.25

$3.59

1-Week Range:

$3.18

$5.38

52-Week Range:

$2.66

$16.00

Elicio Therapeutics Inc Stock (ELTX) Company Profile

Name

Elicio Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(857) 209-0050

Address

451 D STREET, 5TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ELTX's Discussions on Twitter

Compare ELTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELTX Elicio Therapeutics Inc	3.295	74.63M	0	-40.19M	-38.49M	-2.3444
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-26	Initiated	Ladenburg Thalmann	Buy
Mar-10-26	Initiated	Rodman & Renshaw	Buy

Elicio Therapeutics Inc Stock (ELTX) Latest News

Jul 02, 2026

Elicio Therapeutics Prices $15 Million Registered Direct Offering at $3.43; Signs Purchase, Placement Pacts - TradingView

Jul 02, 2026

Elicio Therapeutics (ELTX) prices $15M registered direct equity offering - Stock Titan

Jul 02, 2026

Elicio Therapeutics Prices $15 Million Direct Offering - marketscreener.com

Jul 02, 2026

Elicio locks in $15M to fund Phase 1 KRAS cancer trial - Stock Titan

Jul 02, 2026

Elicio Therapeutics prices $15M stock offering to fund cancer immunotherapy trials. - Pluang

Jul 02, 2026

Elicio Therapeutics raises $15M in registered direct offering - Investing.com

Jul 02, 2026

Elicio Therapeutics raises $15M in registered direct offering By Investing.com - Investing.com Nigeria

Jul 02, 2026

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering - GlobeNewswire

Jul 02, 2026

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering - GlobeNewswire Inc.

Jul 02, 2026

Jul 01, 2026

Price to book forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX - TradingView

Jul 01, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jul 01, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Jul 01, 2026

Jun 30, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc.ELTX - FinancialContent

Jun 30, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therap - The National Law Review

Jun 30, 2026

Jun 29, 2026

Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026